Capricor Therapeutics Inc (NASDAQ:CAPR) Given Average Recommendation of “Buy” by Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPRGet Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.50.

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald raised their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Piper Sandler assumed coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd.

View Our Latest Report on CAPR

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 65.21 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $3,806,000. Vanguard Group Inc. lifted its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the period. PFM Health Sciences LP purchased a new stake in Capricor Therapeutics in the third quarter valued at $2,324,000. State Street Corp grew its position in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Capricor Therapeutics during the 2nd quarter valued at about $426,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Price Performance

Shares of CAPR stock opened at $19.01 on Friday. The stock’s 50-day moving average is $18.03 and its 200 day moving average is $9.41. Capricor Therapeutics has a 1-year low of $2.90 and a 1-year high of $23.40. The company has a market cap of $864.38 million, a P/E ratio of -17.93 and a beta of 4.00.

About Capricor Therapeutics

(Get Free Report

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Recommended Stories

Analyst Recommendations for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.